Abstract:Aim: Chronic obstructive pulmonary disease (COPD) is one of the most widespread diseases, its pathogenesis is very complex and unclear. The purpose of this study was to find the new biomarkers of COPD and elucidate its role in the pathogenesis and treatment of COPD. Methods: 221 patients with COPD and 60 healthy people were enrolled in the study. Non-targeted analysis of metabolites in plasma of COPD patients and healthy people were performed by ultra-high performance liquid chromatography (UPLC) and quadrupole time-of-flight mass spectrometry (TOF-MS). The differential metabolites were analyzed and identified by multivariate analysis between healthy people and COPD patients. The role and mechanisms of the differential metabolic biomarkers in COPD were investigated and verified with COPD rats, arginosuccinate synthetase 1(ASS-l) KO mice and bronchial epithelial cells (BECs) in vivo and in vitro. Meanwhile, whether the differential biomarkers can be the potential treatment targets for COPD was also investigated. Results: 85 differentials metabolites were identified between healthy people and COPD patients by metabonomics. L-arginine (LA) was the most obvious differential metabolite among the 85 metabolites. At the same time, it was found that LA had protective effects on COPD with in vivo and in vitro experiments. Silencing ASS-1, which regulates LA metabolism, and α-methy-DL-aspartic (NHLA), an ASS-1 inhibitor, canceled the protective effect of LA on COPD. The mechanism of LA in COPD was related to the inhibition of ROS/NLRP3/NF-κB signaling pathway. Conclusion: L-arginine (LA) as a key metabolic marker is identified in COPD patients. LA has a protective effect on COPD, its mechanism is related to the regulation of ROS/NLRP3/NF-κB signaling pathway. LA may be a novel target for the treatment of COPD.Funding Information: This research was supported by National Natural Science Foundation of China (81400800).Declaration of Interests: The authors declare that they have no conflict of interest.Ethics Approval Statement: All patient experiments were performed under the guidance of the Helsinki Declaration and approved by the Research Council of Affiliated Nanjing Hospital of Nanjing University of Chinese Medicine (KY2017019). All animal experiments were performed in accordance with the principles of the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH Publications, eighth edition, 2011) and were approved by the Research Council and Animal Care and Use Committee of Affiliated Nanjing Hospital of Nanjing University of Chinese Medicine and Army Medical Center, Army Medical University.

L-ascorbate Alleviates Chronic Obstructive Pulmonary Disease through the EGF/PI3K/AKT Signaling Axis

Zl-n-91, a Selective Phosphodiesterase 4 Inhibitor, Suppresses Inflammatory Response in a COPD-like Rat Model.

Effective-Component Compatibility of Bufei Yishen Formula III Combined with Electroacupuncture Suppresses Inflammatory Response in Rats with Chronic Obstructive Pulmonary Disease via Regulating SIRT1/NF- κ B Signaling

Lijing-Anfei Decoction Attenuates COPD  in a Mouse Model: Network Pharmacology  Analysis, Molecular Docking,  and Experimental Validation

l-Arginine, as an essential amino acid, is a potential substitute for treating COPD via regulation of ROS/NLRP3/NF-κB signaling pathway

L-Arginine, as an Important Metabolic Biomarker, Participates in the Pathological Process of Chronic Obstructive Pulmonary Disease

Metabolomics Screening Identifies Reducedl-Carnitine to Be Associated with Progressive Emphysema

The antioxidant N-acetylcysteine promotes immune response and inhibits epithelial-mesenchymal transition to alleviate pulmonary fibrosis in chronic obstructive pulmonary disease by suppressing the VWF/p38 MAPK axis

Therapeutic potential of Cordyceps sinensis targeting oxidative stress and inflammatory response in the treatment of COPD rats: insights from metabolomics analysis

S-Allylmercapto-N-acetylcysteine ameliorates elastase-induced chronic obstructive pulmonary disease in mice via regulating autophagy

As-703026 Inhibits Lps-Induced Tnfa Production Through Mek/Erk Dependent And Independent Mechanisms

Preliminary therapeutic and mechanistic evaluation of S-allylmercapto-N-acetylcysteine in the treatment of pulmonary emphysema.

Astragaloside IV protects against lung injury and pulmonary fibrosis in COPD by targeting GTP-GDP domain of RAS and downregulating the RAS/RAF/FoxO signaling pathway

Effects of Tibetan medicine Longdan zhike tablet on chronic obstructive pulmonary disease through MAPK pathway

Inactivation of the TGF-β1/ALK5 axis enhances club cell function and alleviates lung tissue damage to ameliorate COPD progression through the MEK/ERK signaling pathway

The Anti-Inflammatory Effect of a Combination of Five Compounds From Five Chinese Herbal Medicines Used in the Treatment of COPD

Electroacupuncture attenuates pulmonary vascular remodeling in a rat model of chronic obstructive pulmonary disease via the VEGF/PI3K/Akt pathway

AS-703026 Inhibits LPS-Induced TNFα Production through MEK/ERK Dependent and Independent Mechanisms.

Ethyl acetate fraction of Thesium chinense Turcz. alleviates chronic obstructive pulmonary disease through inhibition of ferroptosis mediated by activating Nrf2/SLC7A11/GPX4 axis

[Metabonomics Research on Lung Tissue of Rats with Acute Exacerbation of Chronic Obstructive Pulmonary Disease Treated with Mineral Chinese Medicine Chloriti Lapis].

Celastrol Alleviates Chronic Obstructive Pulmonary Disease by Inhibiting Cellular Inflammation Induced by Cigarette Smoke Via the Ednrb/Kng1 Signaling Pathway